• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

可见光和谷胱甘肽双重响应的聚合物偶联替莫唑胺中间体用于胶质母细胞瘤化疗。

Visible Light and Glutathione Dually Responsive Delivery of a Polymer-Conjugated Temozolomide Intermediate for Glioblastoma Chemotherapy.

机构信息

Key Laboratory of High Performance Polymer Material and Technology of Ministry of Education, Department of Polymer Science & Engineering, School of Chemistry & Chemical Engineering, Nanjing University, Nanjing 210023, China.

出版信息

ACS Appl Mater Interfaces. 2021 Dec 1;13(47):55851-55861. doi: 10.1021/acsami.1c16962. Epub 2021 Nov 17.

DOI:10.1021/acsami.1c16962
PMID:34788006
Abstract

Temozolomide (TMZ) is a prodrug of 5-(3-methyltriazene-1-yl)imidazole-4-carboxamide (MTIC, short-lived) and used as a first-line therapy drug for glioblastoma multiforme (GBM). However, little progress has been made in regulating the kinetics of TMZ to MTIC degradation to improve the therapeutic effect, particularly in the case of TMZ-resistant GBM. In this work, we introduced a strategy to cage MTIC by N-acylation of the triazene moiety to boost the MTIC stability, designed a diblock copolymer-based MTIC prodrug installed with a disulfide linkage, and achieved self-assembled polymer micelles without the concern of MTIC leakage under physiological conditions. Polymer micelles could be induced to disassemble by stimuli factors such as glutathione (GSH) and visible light irradiation through thiol/sulfide exchange and homolytic sulfide scission mechanisms, which contributed to MTIC release in GSH-dependent and GSH-independent pathways. The in vitro results demonstrated that microenvironment-responsive polymeric micelles benefited the suppression of both TMZ-sensitive and TMZ-resistant GBM cells. The chemistry of polymer-MTIC prodrug provided a new option for TMZ-based glioma treatment.

摘要

替莫唑胺(TMZ)是 5-(3-甲基三嗪-1-基)咪唑-4-甲酰胺(MTIC,短寿命)的前体药物,用作多形性胶质母细胞瘤(GBM)的一线治疗药物。然而,在调节 TMZ 向 MTIC 降解的动力学以提高治疗效果方面,几乎没有取得进展,特别是在 TMZ 耐药的 GBM 中。在这项工作中,我们通过三嗪部分的 N-酰化引入了一种将 MTIC 笼封的策略,以提高 MTIC 的稳定性,设计了一种带有二硫键的基于两亲嵌段共聚物的 MTIC 前药,并在生理条件下实现了自组装聚合物胶束,而无需担心 MTIC 泄漏。聚合物胶束可以通过谷胱甘肽(GSH)和可见光照射等刺激因素诱导解组装,通过巯基/硫醚交换和均裂硫醚断裂机制促进 MTIC 的释放,这有助于 GSH 依赖和非依赖途径中的 MTIC 释放。体外结果表明,对微环境响应的聚合物胶束有利于抑制 TMZ 敏感和 TMZ 耐药的 GBM 细胞。聚合物-MTIC 前药的化学为基于 TMZ 的脑肿瘤治疗提供了新的选择。

相似文献

1
Visible Light and Glutathione Dually Responsive Delivery of a Polymer-Conjugated Temozolomide Intermediate for Glioblastoma Chemotherapy.可见光和谷胱甘肽双重响应的聚合物偶联替莫唑胺中间体用于胶质母细胞瘤化疗。
ACS Appl Mater Interfaces. 2021 Dec 1;13(47):55851-55861. doi: 10.1021/acsami.1c16962. Epub 2021 Nov 17.
2
Polymer-Drug Conjugates Codeliver a Temozolomide Intermediate and Nitric Oxide for Enhanced Chemotherapy against Glioblastoma Multiforme.聚合物-药物偶联物共递送替莫唑胺中间体和一氧化氮,增强胶质母细胞瘤多形性的化疗效果。
ACS Appl Bio Mater. 2024 Mar 18;7(3):1810-1819. doi: 10.1021/acsabm.3c01219. Epub 2024 Feb 25.
3
Enhanced Copper-Temozolomide Interactions by Protein for Chemotherapy against Glioblastoma Multiforme.增强铜-替莫唑胺相互作用的蛋白质用于多形性胶质母细胞瘤的化疗。
ACS Appl Mater Interfaces. 2019 Nov 13;11(45):41935-41945. doi: 10.1021/acsami.9b14849. Epub 2019 Nov 4.
4
Temozolomide-Doxorubicin Conjugate as a Double Intercalating Agent and Delivery by Apoferritin for Glioblastoma Chemotherapy.替莫唑胺-阿霉素偶联物作为双重嵌入剂,并通过脱铁铁蛋白递送至神经胶质瘤化疗。
ACS Appl Mater Interfaces. 2020 Aug 5;12(31):34599-34609. doi: 10.1021/acsami.0c08531. Epub 2020 Jul 23.
5
Biomimetic Polymer-Templated Copper Nanoparticles Stabilize a Temozolomide Intermediate for Chemotherapy against Glioblastoma Multiforme.仿生聚合物模板化铜纳米粒子稳定替莫唑胺中间体用于多形性胶质母细胞瘤的化学疗法。
ACS Appl Bio Mater. 2021 Nov 15;4(11):8004-8012. doi: 10.1021/acsabm.1c00915. Epub 2021 Oct 22.
6
Development of a PAMAM Dendrimer for Sustained Release of Temozolomide against Experimental Murine Lymphoma: Assessment of Therapeutic Efficacy.载有替莫唑胺的树枝状高分子聚合物的研制及其用于实验性鼠淋巴瘤的缓释:疗效评估。
ACS Appl Bio Mater. 2021 Mar 15;4(3):2628-2638. doi: 10.1021/acsabm.0c01599. Epub 2021 Mar 4.
7
Temozolomide Efficacy and Metabolism: The Implicit Relevance of Nanoscale Delivery Systems.替莫唑胺的疗效和代谢:纳米递药系统的潜在相关性。
Molecules. 2022 May 30;27(11):3507. doi: 10.3390/molecules27113507.
8
Enhanced Anti-Tumor Activity in Mice with Temozolomide-Resistant Human Glioblastoma Cell Line-Derived Xenograft Using SN-38-Incorporated Polymeric Microparticle.载有 SN-38 的聚合物胶束用于对替莫唑胺耐药的人胶质母细胞瘤细胞系衍生异种移植物的小鼠中增强抗肿瘤活性。
Int J Mol Sci. 2021 May 24;22(11):5557. doi: 10.3390/ijms22115557.
9
Novel structural-related analogs of PFI-3 (SRAPs) that target the BRG1 catalytic subunit of the SWI/SNF complex increase the activity of temozolomide in glioblastoma cells.新型结构相关的 PFI-3(SRAPs)类似物靶向 SWI/SNF 复合物的 BRG1 催化亚基,增加胶质母细胞瘤细胞中替莫唑胺的活性。
Bioorg Med Chem. 2022 Jan 1;53:116533. doi: 10.1016/j.bmc.2021.116533. Epub 2021 Nov 27.
10
Delivery of Temozolomide and N3-Propargyl Analog to Brain Tumors Using an Apoferritin Nanocage.载有替莫唑胺和 N3-炔丙基类似物的去铁铁蛋白纳米笼递送至脑肿瘤。
ACS Appl Mater Interfaces. 2020 Mar 18;12(11):12609-12617. doi: 10.1021/acsami.0c01514. Epub 2020 Mar 4.

引用本文的文献

1
Overcoming temozolomide resistance in glioma: recent advances and mechanistic insights.克服胶质瘤中的替莫唑胺耐药性:最新进展与机制洞察
Acta Neuropathol Commun. 2025 Jun 5;13(1):126. doi: 10.1186/s40478-025-02046-4.
2
Research Progress of Disulfide Bond Based Tumor Microenvironment Targeted Drug Delivery System.基于二硫键的肿瘤微环境靶向药物传递系统的研究进展。
Int J Nanomedicine. 2024 Jul 24;19:7547-7566. doi: 10.2147/IJN.S471734. eCollection 2024.
3
Stimuli-sensitive polymer prodrug nanocarriers by reversible-deactivation radical polymerization.
刺激响应性聚合物前药纳米载体的可逆失活自由基聚合。
Chem Soc Rev. 2024 Jun 17;53(12):6511-6567. doi: 10.1039/d2cs01060g.
4
Mechanisms of Resistance and Current Treatment Options for Glioblastoma Multiforme (GBM).多形性胶质母细胞瘤(GBM)的耐药机制及当前治疗选择
Cancers (Basel). 2023 Apr 1;15(7):2116. doi: 10.3390/cancers15072116.